Redmile Group, LLC Aprea Therapeutics, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$2.87 - $5.58 $1.99 Million - $3.88 Million	-694,918 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.73 - $8.15 $2.71 Million - $4.68 Million	-573,800 Reduced 45.23%	694,918 $3.54 Million
Q4 2020 Feb 16, 2021	SELL	$4.92 - $30.67 $4.92 Million - $30.7 Million	-1,000,000 Reduced 44.08%	1,268,718 $6.24 Million
Q4 2019 Feb 14, 2020	BUY	$18.94 - $49.53 $43 Million - $112 Million	2,268,718 New	2,268,718 $104 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,741
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.